Canada approves Biogen Idec's hemophilia treatment

03/21/2014 12:14 PM

02/15/2015 10:43 AM

Canadian authorities have approved Biogen Idec’s Alprolix, which the drug maker says is the first new hemophilia treatment in 17 years. Alprolix, manufactured in Morrisville, is expected to win U.S. approval within three months, the company said.

Canada is the first country to approve Alprolix, an intravenous treatment also awaiting approval in Australia and Japan. The medication is designed to reduce bleeding from hemophilia B, a rare form of the blood-clotting disorder that has been diagnosed in about 28,000 people worldwide.

Cambridge, Mass.-based Biogen employs more than 6,000 people worldwide, including 1,200 in the Triangle. Biogen’s Morrisville facility currently makes two injection treatments for multiple sclerosis and will also manufacture Alprolix as well as a hemophilia A treatment that’s expected to win U.S. approval this year.

Biogen’s shares closed Friday at $318.53, down $28.51. The stock is up 14 percent this year.

Hemophilia B is a rare inherited blood disorder that can lead to recurring and prolonged bleeding. People afflicted with it have low amounts of clotting factor IX, whereas the more common form, Hemophilia A, is characterized by low levels of clotting factor VIII.

Alprolix was tested on 123 men and boys aged 12 and older in the largest study of hemophilia B ever completed. Alprolix is injected between once and twice a week and is designed to control or prevent bleeding episodes.

The company said that 90 percent of all bleeding episodes in type B patients were controlled by a single Alprolix infusion.

Join the Discussion

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service